| Literature DB >> 35005314 |
Simon A Carter1,2, Claris Teng2, Talia Gutman1,2, Charlotte Logeman2, Dan Cattran3,4, Liz Lightstone5, Arvind Bagga6, Sean J Barbour7, Jonathan Barratt8,9, John Boletis10, Dawn J Caster11, Rosanna Coppo12, Fernando C Fervenza13, Jürgen Floege14, Michelle A Hladunewich3,15, Jonathan J Hogan16, A Richard Kitching17,18, Richard A Lafayette19,20, Ana Malvar21, Jai Radhakrishnan22, Brad H Rovin23, Nicole Scholes-Robertson1,2, Hernán Trimarchi24, Hong Zhang25, Karolis Azukaitis26, Yeoungjee Cho27,28,29, Andrea K Viecelli27,28, Louese Dunn30, David Harris31,32, David W Johnson27,28,29, Peter G Kerr18, Paul Laboi33, Jessica Ryan17,18, Jenny I Shen34, Lorena Ruiz34, Angela Yee-Moon Wang35, Achilles Hoi Kan Lee36, Samuel Fung Ka Shun37, Matthew Ka-Hang Tong38, Armando Teixeira-Pinto1,2, Martin Wilkie39, Stephen I Alexander2, Jonathan C Craig40, Adam Martin2, Allison Tong1,2.
Abstract
INTRODUCTION: Patients with glomerular disease experience symptoms that impair their physical and mental health while managing their treatments, diet, appointments and monitoring general and specific indicators of health and their illness. We sought to describe the perspectives of patients and their care partners on self-management in glomerular disease.Entities:
Keywords: focus groups; glomerulonephritis; personal autonomy; self-management; therapeutic alliance
Year: 2021 PMID: 35005314 PMCID: PMC8720796 DOI: 10.1016/j.ekir.2021.10.011
Source DB: PubMed Journal: Kidney Int Rep ISSN: 2468-0249
Participant demographic and clinical characteristics
| Participant characteristics | All |
|---|---|
| Country | |
| Australia | 50 (37) |
| Hong Kong | 22 (16) |
| United Kingdom | 29 (22) |
| United States | 33 (25) |
| Patient | 101 (75) |
| Care partner or family member | 33 (25) |
| Self-identified gender | |
| Male | 66 (49) |
| Female | 68 (51) |
| Age group (yr) | 32 (24) |
| 18–39 | 57 (43) |
| 40–59 | 42 (32) |
| 60–79 | 2 (2) |
| >80 | |
| Ethnicity | |
| White | 61 (46) |
| Asian (Central, South, East) | 38 (28) |
| Hispanic | 23 (17) |
| African/African American | 6 (4) |
| Other | 6 (4) |
| Educational attainment | |
| Primary school | 21 (21) |
| Secondary school (grade 10) | 26 (26) |
| Certificate/diploma | 22 (22) |
| University degree | 30 (30) |
| Employment | |
| Full time or part time | 40 (40) |
| Student | 4 (4) |
| Not employed | 21 (21) |
| Other/retired | 34 (34) |
| Income (USD) | |
| <60,000 | 73 (73) |
| 60,000–150,000 | 8 (8) |
| >150,000 | 2 (2) |
| Not stated | 18 (18) |
| Type of glomerular disease | |
| Lupus nephritis | 18 (18) |
| ANCA-associated vasculitis | 18 (18) |
| IgA nephropathy | 18 (18) |
| Focal segmental glomerulosclerosis | 10 (10) |
| Membranous nephropathy | 6 (6) |
| Minimal change nephropathy | 5 (5) |
| Membranoproliferative glomerulonephritis | 6 (6) |
| C3 glomerulopathy | 5 (5) |
| Antiglomerular basement membrane disease | 1 (1) |
| IgG4-related disease | 1 (1) |
| Years since diagnosis | |
| ≤2 | 30 (30) |
| 3–11 | 31 (31) |
| ≥12 | 34 (34) |
| Treatment stage of kidney disease | |
| Chronic kidney disease | 66 (65) |
| Hemodialysis | 14 (14) |
| Peritoneal dialysis | 13 (13) |
| Kidney transplant | 15 (15) |
| Comorbid conditions | |
| Diabetes | 18 (18) |
| Depression/anxiety | 16 (16) |
| Obesity | 14 (14) |
| Cardiovascular disease including stroke | 11 (11) |
| Asthma | 9 (9) |
| Cancer | 6 (6) |
ANCA, antineutrophil cytoplasmic antibody; USD, United States dollar.
Patients only. May not sum to totals as some categories represent overlapping experience. There were 13 patients who did not know their type of glomerular disease. One patient was missing for age; 2 patients had missing data for education, immunosuppression; 6 missing years since diagnosis; 6 missing for kidney disease stage.
Selected illustrative quotations for themes and subthemes
| Empowered in autonomy | |
| Gaining confidence through understanding | You have to be informed. You have to know what’s happening to you and how it’s happening to you.—Patient, United States |
| Taking ownership of disease and treatment | I love that feeling of actually looking for the areas that I can control, because it makes me think I’m contributing something to this in a positive way.—Patient, Australia |
| Learning a positive health approach | One thing you said that was really important is your personal mental attitude toward this. If you come out thinking you’ve had some disaster happen to you, or woe me because my life is now changed, you’re going to wither away. You have to come out positive, because it’s as much about the health, rejuvenation, than anything to do with putting the kidney in your body.—Patient, United Kingdom |
| Overwhelmed by compounding treatment burdens | |
| Financially undermined and depleted | The cost of the medication, that’s a killer, it goes from $6 to $39, and literally you can’t go back to work, you know?—Patient, Australia |
| Demoralized by side effects and harms | Those immunosuppressant drugs are giving me hell. In the last five or more, six to eight years, I’ve been in that hospital about 20 times because of infections. Bladder infections, lung infections, throat infections, ear infections. The last one, that nearly killed me.—Patient, Australia |
| Frustrated by fragmented and inflexible care | I go to a few different clinics—they tend to focus on that particular problem…It may be disastrous for some, for another problem you’ve got.—Patient, United States |
| Fear of possible drug harms | You do wonder sometimes, the amount of chemicals you’re putting in your body. That can’t be good. It’s probably helping. But what else is it doing?—Patient, Australia |
| Striving for stability and normalcy | |
| Making personal sacrifices | [I’m] really sad because I would like to have more kids, but they don’t allow me anymore. I could, but it’s a risk—Patient, United States |
| Maximizing life participation | To be honest, for people who [get to] this stage [of kidney disease], it’s more like you will try your very best to live your life, to do whatever you want when it’s still available.—Patient, Hong Kong |
| Attentiveness to bodily signs | So you don’t end up with big swollen legs, because you spot the froth in urine beforehand. You see them, they treat you, you’re fixed.—Patient, United Kingdom |
| Avoiding precarious health states | Everything is fine because I’m constantly taking that pill. When I wasn’t taking that pill, I was in and out of the hospital. Everything was going wrong.—Patient, United States |
| Integrating medicines into routines | When they decided to give me some extra doses of medication … I forget. I just can’t get into the habit of taking it.—Patient, Australia |
| Necessity of health-sustaining relationships | |
| Buoyed by social support | I’m very lucky, it’s my sister and family who support me. If I don’t have them, I will not be alive until now. Family is very, very important.—Patient, Hong Kong |
| Fulfilling meaningful responsibilities | To be able to participate … you know, the growth of the country and yourself, and get back to work.—Patient, United Kingdom |
| Sharing and normalizing experiences | It’s good listening to other people. I find that’s a big thing for me, I feel very alone. I don’t know many other people who have a similar disease, and I’d really like to be able to talk to other people, you know? It makes a huge difference.—Patient, Australia |
| Seeking a trusting and respectful alliance | I noticed the change in her outlook … I think if you’ve got confidence [in the physician], it improves your outlook to no end. Deal with somebody you can rely on and trust and have great confidence in.—Care partner, Australia |
Figure 1Thematic schema relating the motivators, barriers, and attitudes to self-management in patients with glomerular disease.
Self-management strategies and suggestions for patients with glomerular disease
| Strategy domain | Suggestions to support self-management |
|---|---|
| Increase patients’ knowledge | Provide access to consistent and trustworthy information |
| Support shared decision-making | Ensure health professionals are trained in shared decision-making and communication skills |
| Address medication safety | Preventative approaches to side effects (e.g., vaccination, calcium intake, weight bearing, and bone density checks) |
| Provide new skills | Home monitoring for urinary protein, weight, and blood pressure, where appropriate and with support |
| Increase prioritization among health professionals | Teach self-management frameworks in training programs |
| Provide psychosocial support | Provide regular health-facing updates and avoid a “deficit discourse” |
Suggestions were derived from focus group participants, current practice, and the literature.
Remaining gaps and research priorities for self-management in patients with glomerular disease
| Area of study | Future research questions and aims |
|---|---|
| Identify existing and novel self-management strategies | Identify all relevant existing self-management strategies for patients with glomerular disease from another chronic condition(s) |
| Target population | Which interventions are specific to one type of glomerular disease? Which strategies are relevant across all patients with chronic kidney disease? |
| Identify priorities | Establish a candidate set of self-management strategies (to inform their development) with patients, care partners, and health professionals |
| Co-design interventions | Codesign self-management interventions (individual or bundled) with all stakeholders, including patients, using an appropriate theory |
| Efficacy and cost-effectiveness | Do self-management programs improve health outcomes or delivery of patient care? |
| Co-implementation | What are the provider-level barriers and facilitators to implementation? |